High‐dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT)
| Autor: | Paul Westermann, Matthias Grünewald, Ingolf Cascorbi, Thomas Herdegen, Ruwen Böhm, Henning Ohnesorge, Martin Gleim |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Fibromyalgia Pain Spironolactone Placebo law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Mineralocorticoid receptor Double-Blind Method Randomized controlled trial 030202 anesthesiology law Internal medicine Humans Medicine Clinical significance business.industry medicine.disease Clinical trial Treatment Outcome Anesthesiology and Pain Medicine chemistry Heart failure Female sense organs business 030217 neurology & neurosurgery |
| Zdroj: | European Journal of Pain. 25:1739-1750 |
| ISSN: | 1532-2149 1090-3801 |
| Popis: | BACKGROUND Spironolactone (SPL) is a reversible mineralocorticoid receptor (MR) and androgen receptor (AR) antagonist which attracts pharmacotherapeutic interest not only because of its beneficial effects in heart failure but also because of the pathogenetic roles of MR and AR activities in neuropsychiatric diseases. Recently, beneficial and rapid-onset effects of SPL have been documented in a case series of women with fibromyalgia syndrome (FMS). To reaffirm this observation, we performed a double-blind placebo-controlled randomized clinical trial (RCT). METHODS A total of 69 patients were screened, 56 patients were eligible and randomized to SPL or placebo (each n = 28). Forty-three patients completed the clinical trial to the last visit (n = 21 and n = 22). After a run-in phase of 50 and 100 mg/day, 200 mg/day SPL or placebo were applied between days 7 and 28. Primary outcome was the change in the FIQ-G score (Fibromyalgia Impact Questionnaire, German version). Secondary outcome parameters were the changes in pain (numeric rating scale, NRS), mood (ADS), quality of life (SF-36) and change in FIQ scores 14 days after the end of the medication. RESULTS SPL of 200 mg/day did not change significantly either the primary or the secondary end points. SPL evoked a transient rise in serum potassium and a transient fall in GFR maximal after 2 weeks, but without clinical relevance. CONCLUSIONS SPL at 200 mg/day does not improve symptoms in women with FMS, but was considered not to cause harm. SIGNIFICANCE The mineralocorticoid receptor and androgen receptor antagonist spironolactone is repeatedly tested for its therapeutic effectivity against neuropsychiatric disorders. The present RCT demonstrated that 200 mg spironolactone does not change the symptoms of the fibromyalgia syndrome (FMS) in adult women. Between 2 and 4 weeks, spironolactone evokes a transient decrease in GFR and increase in serum potassium. Spironolactone cannot be recommended for the treatment of FMS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text